Fulcrum Therapeutics Share Price Today
(NASDAQ: FULC)

Name: Fulcrum Therapeutics Share Price Today (NASDAQ: FULC) - Fulcrum Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Fulcrum Therapeutics share price is $3.53 & ₹301.66 as on 26 Apr 2025, 2.30 'hrs' IST

$3.53

▲

0.02

(0.57%)

Market is closed - opens 7 PM, 28 Apr 2025

View live Fulcrum Therapeutics share price in Dollar and Rupees. Guide to invest in Fulcrum Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Fulcrum Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Fulcrum Therapeutics share price movements

Today's Low: $3.39
Today's High: $3.53
$3.53
4.11%
Downside
Day's Volatility :4.11%
Upside
0.0%
52 Weeks Low: $2.32
52 Weeks High: $10.13
$3.53
34.42%
Downside
52 Weeks Volatility :77.15%
Upside
65.15%

Fulcrum Therapeutics (FULC) Returns

Period	Fulcrum Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.39%	-4.8%	0.0%
6 Months	8.33%	-7.5%	0.0%
1 Year	-50.84%	-1.8%	0.0%
3 Years	-64.72%	2.1%	-9.5%

Fulcrum Therapeutics (FULC) Key Statistics

in dollars & INR

Previous Close	$3.51
Open	$3.5
Today's High	$3.53
Today's Low	$3.385
Market Capitalization	$197.0M
Today's Volume	$215.4K
52 Week High	$10.13
52 Week Low	$2.315
Revenue TTM	$80.0M
EBITDA	$-18.2M
Earnings Per Share (EPS)	$-0.16
Profit Margin	-12.16%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-4.07%

How to invest in Fulcrum Therapeutics Stock (FULC) from India?

It is very easy for Indian residents to invest directly in Fulcrum Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Fulcrum Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Fulcrum Therapeutics or FULC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Fulcrum Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Fulcrum Therapeutics shares which would translate to 0.242 fractional shares of Fulcrum Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Fulcrum Therapeutics, in just a few clicks!

Returns in Fulcrum Therapeutics (FULC) for Indian investors in Rupees

The Fulcrum Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Fulcrum Therapeutics investment value today

Current value as on today

₹51,998

Returns

₹48,002

(-48%)

Returns from Fulcrum Therapeutics Stock

₹50,560 (-50.56%)

Dollar Returns

₹2,558 (+2.56%)

Indian investors sentiment towards Fulcrum Therapeutics (FULC)

33%

Period: Mar 26, 2025 to Apr 25, 2025. Change in 30 Days versus previous period

Search interest for Fulcrum Therapeutics Stock from India on INDmoney has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Fulcrum Therapeutics

RA Capital Management, LLC
18.95%
TCG Crossover Management, LLC
9.73%
BlackRock Inc
9.58%
Nantahala Capital Management, LLC
8.85%
Suvretta Capital Management, LLC
6.18%
Vanguard Group Inc
6.02%

Analyst Recommendation on Fulcrum Therapeutics

Rating

Trend

Buy

78%Buy

14%Hold

7%Sell

Based on 14 Wall street analysts offering stock ratings for Fulcrum Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Fulcrum Therapeutics Stock (FULC)

What analysts predicted

Upside of 60.53%

Target:

$5.67

Current:

$3.53

Insights on Fulcrum Therapeutics Stock (Ticker Symbol: FULC)

Price Movement
In the last 1 month, FULC stock has moved up by 12.9%
Increasing Revenue
Revenue is up for the last 3 quarters, 759.0K → 80.0M (in $), with an average increase of 55.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -21.69M → -16.56M (in $), with an average increase of 31.0% per quarter
FULC vs ONC (1 yr)
In the last 1 year, Beone Medicines Ltd has given 72.4% return, outperforming this stock by 123.2%
FULC vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.3% return, outperforming this stock by 125.2%
Price to Sales
ForFULC every $1 of sales, investors are willing to pay $2.7, whereas for Beone Medicines Ltd, the investors are paying $6.8 for every $1 of sales.

Fulcrum Therapeutics Technicals Summary

Sell

Neutral

Buy

Fulcrum Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Fulcrum Therapeutics (FULC) Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Fulcrum Therapeutics Inc	13.59%	8.33%	-50.84%	-64.72%	-70.73%
Regeneron Pharmaceuticals, Inc.	-5.67%	-35.41%	-32.09%	-10.95%	9.54%
Beone Medicines Ltd	-2.45%	17.93%	66.79%	62.33%	55.25%
Vertex Pharmaceuticals Incorporated	-2.01%	3.38%	23.9%	84.27%	83.41%
Alnylam Pharmaceuticals, Inc.	-10.48%	-15.44%	69.29%	56.6%	70.01%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Fulcrum Therapeutics Inc	NA	NA	NA	-1.25	-0.04	-0.05	NA	4.5
Regeneron Pharmaceuticals, Inc.	15.27	15.27	0.94	39.99	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.09	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	17.95	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.72	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Fulcrum Therapeutics Inc	Buy	$197.0M	-70.73%	NA	-12.16%
Regeneron Pharmaceuticals, Inc.	Buy	$64.0B	9.54%	15.27	31.07%
Beone Medicines Ltd	NA	$28.7B	55.25%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$126.6B	83.41%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.3B	70.01%	NA	-12.37%

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Organization	Fulcrum Therapeutics
Employees	45
CEO	Mr. Alexander C. Sapir
Industry	Health Technology

Management People of Fulcrum Therapeutics

Name	Title
Mr. Alexander C. Sapir	CEO, President & Director
Mr. Alan A. Musso C.M.A., CPA	Chief Financial Officer
Mr. Curtis G. Oltmans J.D.	Senior VP, Chief Legal Officer & Corporate Secretary
Mr. Mel Hayes	Executive Vice President of Patient Experience
Dr. Bradley E. Bernstein M.D., Ph.D.	Founder
Dr. Michael R. Green	Founder
Dr. Rudolf Jaenisch M.D., Ph.D.	Founder
Dr. Tsun-Huei Lee M.D., Ph.D.	Founder
Dr. Danny Reinberg	Founder
Mr. Gregory Tourangeau	Controller & Principal Accounting Officer

Important FAQs about investing in FULC Stock from India :

What is Fulcrum Therapeutics share price today?

Fulcrum Therapeutics share price today stands at $3.53, Open: $3.50 ; Previous Close: $3.51 ; High: $3.53 ; Low: $3.39 ; 52 Week High: $10.13 ; 52 Week Low: $2.32.

The stock opens at $3.50, after a previous close of $3.51. The stock reached a daily high of $3.53 and a low of $3.39, with a 52-week high of $10.13 and a 52-week low of $2.32.

Can Indians buy Fulcrum Therapeutics shares?

Yes, Indians can invest in the Fulcrum Therapeutics (FULC) from India.

With INDmoney, you can buy Fulcrum Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Fulcrum Therapeutics at zero transaction cost.

How can I buy Fulcrum Therapeutics shares from India?

It is very easy to buy Fulcrum Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Fulcrum Therapeutics (FULC) be purchased?

Yes, you can buy fractional shares of Fulcrum Therapeutics with INDmoney app.

What are the documents required to start investing in Fulcrum Therapeutics stocks?

To start investing in Fulcrum Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.